TY - JOUR
T1 - The Correlation Between Immunohistochemistry Findings and Metastasis in Squamous Cell Carcinoma
T2 - A Review
AU - Lobl, Marissa
AU - Grinnell, Madison
AU - Phillips, Andrew
AU - Abels, Joshua
AU - Wysong, Ashley
N1 - Publisher Copyright:
Copyright © 2020 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - BACKGROUND: Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer. Only 2% to 5% of SCCs metastasize; however, those do carry a poor prognosis. Immunohistochemistry (IHC) is widely used by pathologists to characterize skin cancers and provide clinically useful information. OBJECTIVE: To evaluate the potential prognostic associations between IHC findings and metastasis in SCC. METHODS: Searches were conducted in MEDLINE via PubMed for articles published between 1999 and 2019. Search criteria included key words "immunohistochemistry" and "cutaneous squamous cell carcinoma." Six hundred and fifty-three articles were returned and screened, which ultimately left 31 for inclusion in our manuscript. RESULTS: Thirty-one articles analyzed in this review included a discussion of the expression of a particular IHC marker and the associated risk of metastasis and/or clinical utility of IHC markers in SCC, especially metastatic SCC. Markers that had several or more studies supporting clinical utility were E-cadherin, podoplanin, CD8+ T cells, PD-L1, epidermal growth factor receptor, and Cyclin D1. CONCLUSION: Immunohistochemistry profiling of SCC may be useful in select cases when providing a prognosis remains challenging and in identification of potential therapeutic targets for high-risk or metastatic tumors.
AB - BACKGROUND: Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer. Only 2% to 5% of SCCs metastasize; however, those do carry a poor prognosis. Immunohistochemistry (IHC) is widely used by pathologists to characterize skin cancers and provide clinically useful information. OBJECTIVE: To evaluate the potential prognostic associations between IHC findings and metastasis in SCC. METHODS: Searches were conducted in MEDLINE via PubMed for articles published between 1999 and 2019. Search criteria included key words "immunohistochemistry" and "cutaneous squamous cell carcinoma." Six hundred and fifty-three articles were returned and screened, which ultimately left 31 for inclusion in our manuscript. RESULTS: Thirty-one articles analyzed in this review included a discussion of the expression of a particular IHC marker and the associated risk of metastasis and/or clinical utility of IHC markers in SCC, especially metastatic SCC. Markers that had several or more studies supporting clinical utility were E-cadherin, podoplanin, CD8+ T cells, PD-L1, epidermal growth factor receptor, and Cyclin D1. CONCLUSION: Immunohistochemistry profiling of SCC may be useful in select cases when providing a prognosis remains challenging and in identification of potential therapeutic targets for high-risk or metastatic tumors.
UR - http://www.scopus.com/inward/record.url?scp=85101763542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101763542&partnerID=8YFLogxK
U2 - 10.1097/DSS.0000000000002850
DO - 10.1097/DSS.0000000000002850
M3 - Review article
C2 - 33165065
AN - SCOPUS:85101763542
VL - 47
SP - 313
EP - 318
JO - Journal of Dermatologic Surgery and Oncology
JF - Journal of Dermatologic Surgery and Oncology
SN - 1076-0512
IS - 3
ER -